DK3362569T3 - Cxcr6-transducerede t-celler til målrettet tumorterapi - Google Patents

Cxcr6-transducerede t-celler til målrettet tumorterapi Download PDF

Info

Publication number
DK3362569T3
DK3362569T3 DK16793764.8T DK16793764T DK3362569T3 DK 3362569 T3 DK3362569 T3 DK 3362569T3 DK 16793764 T DK16793764 T DK 16793764T DK 3362569 T3 DK3362569 T3 DK 3362569T3
Authority
DK
Denmark
Prior art keywords
cxcr6
transduced
cells
tumor therapy
targeted tumor
Prior art date
Application number
DK16793764.8T
Other languages
Danish (da)
English (en)
Inventor
Simon Grassmann
Moritz Rapp
Stefan Endres
Sebastian Kobold
Original Assignee
Univ Muenchen Ludwig Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Ludwig Maximilians filed Critical Univ Muenchen Ludwig Maximilians
Application granted granted Critical
Publication of DK3362569T3 publication Critical patent/DK3362569T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4219—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Output Control And Ontrol Of Special Type Engine (AREA)
  • Developmental Biology & Embryology (AREA)
DK16793764.8T 2015-10-16 2016-10-14 Cxcr6-transducerede t-celler til målrettet tumorterapi DK3362569T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15190179 2015-10-16
PCT/EP2016/074644 WO2017064222A1 (en) 2015-10-16 2016-10-14 Cxcr6-transduced t cells for targeted tumor therapy

Publications (1)

Publication Number Publication Date
DK3362569T3 true DK3362569T3 (da) 2021-10-18

Family

ID=54359823

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16793764.8T DK3362569T3 (da) 2015-10-16 2016-10-14 Cxcr6-transducerede t-celler til målrettet tumorterapi

Country Status (8)

Country Link
US (1) US11723922B2 (enExample)
EP (1) EP3362569B1 (enExample)
JP (2) JP7018387B2 (enExample)
AU (2) AU2016336868B2 (enExample)
CA (1) CA3001507C (enExample)
DK (1) DK3362569T3 (enExample)
ES (1) ES2895901T3 (enExample)
WO (1) WO2017064222A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200054677A1 (en) * 2017-02-21 2020-02-20 The University Of Adelaide T cells expressing chemokine receptors for treating cancer
AU2018248672B2 (en) * 2017-04-05 2021-09-30 Korea Research Institute Of Bioscience And Biotechnology NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
US20210002609A1 (en) * 2017-12-05 2021-01-07 Caribou Biosciences, Inc. Modified lymphocytes
US20210130438A1 (en) * 2019-10-28 2021-05-06 The Broad Institute, Inc. Pan-cancer t cell exhaustion genes
CN116333999A (zh) * 2020-07-14 2023-06-27 广州泛恩生物科技有限公司 基于cxcl13阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
CN113736740A (zh) * 2021-07-27 2021-12-03 天津市肿瘤医院（天津医科大学肿瘤医院） 胰腺癌稳转细胞系及其构建方法和应用
US20250152629A1 (en) * 2022-02-15 2025-05-15 Memorial Sloan-Kettering Cancer Center Compositions including killer innate-like t cells and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696244B2 (en) * 1997-07-17 2004-02-24 New York University G-coupled receptors associated with retroviral entry into cells, and therapeutic uses thereof
DE19822115B4 (de) 1998-05-08 2004-04-08 Heinrich-Pette-Institut Retrovirale Gentransfervektoren
US8003770B2 (en) 2005-09-13 2011-08-23 Mie University T-cell receptor and nucleic acid encoding the receptor
EP2318434A1 (en) 2008-07-31 2011-05-11 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Her2/neu specific t cell receptors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
ES2696000T3 (es) 2011-04-08 2019-01-11 Us Health Receptores de antígenos quiméricos anti-variante III de receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
EP2768863B1 (en) 2011-10-20 2017-09-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd22 chimeric antigen receptors
AU2013235726B2 (en) 2012-03-23 2017-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
RU2650805C2 (ru) 2012-04-11 2018-04-17 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
ES2905557T3 (es) 2013-08-26 2022-04-11 Hinrich Abken Receptor de antígeno quimérico anti-CD30 y su uso

Also Published As

Publication number Publication date
AU2016336868A1 (en) 2018-03-15
JP2022008805A (ja) 2022-01-14
CA3001507A1 (en) 2017-04-20
JP2018531016A (ja) 2018-10-25
CA3001507C (en) 2023-09-19
EP3362569B1 (en) 2021-09-01
EP3362569A1 (en) 2018-08-22
WO2017064222A1 (en) 2017-04-20
AU2022205240A1 (en) 2022-09-29
JP7018387B2 (ja) 2022-02-10
US20180256645A1 (en) 2018-09-13
AU2016336868B2 (en) 2022-04-14
US11723922B2 (en) 2023-08-15
ES2895901T3 (es) 2022-02-23

Similar Documents

Publication Publication Date Title
IL259017A (en) Cancer cure is intended
EP3651772A4 (en) ANTI-CANCER POLYTHERAPY
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
EP3463464A4 (en) ASSOCIATION TREATMENT
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
DK3262066T4 (da) Genterapi
EP3359168A4 (en) THERAPEUTIC COMPOUNDS AND METHOD
DK3240801T3 (da) Kombinationstumorimmunterapi
PT3283527T (pt) Terapêutica de combinação para o cancro
DK3289080T3 (da) Genterapi til autosomalt dominante sygdomme
DK3594238T3 (da) Antistofsammensætninger til tumorbehandling
DK3107563T3 (da) Glycomålrettede terapeutiske midler
MA39483A (fr) Agents thérapeutiques cibles
SMT202400506T1 (it) Terapia genica
KR20180084772A (ko) 암 치료를 위한 조합 치료법
DK3362569T3 (da) Cxcr6-transducerede t-celler til målrettet tumorterapi
PL3622953T3 (pl) Leczenie skojarzone nowotworu
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
SI3612237T1 (sl) Genska terapija
EP3413927A4 (en) CANCER THERAPY
DK3393478T3 (da) Kombinationsterapi
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
EP3310915A4 (en) TUMOR IMMUNOTHERAPY
EP3398546A4 (en) TUMORKRYOABLATIONSKATHETER
EP3362091A4 (en) COMBINATION THERAPY